Vanguard Group’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-920,517
| Closed | -$643K | – | 4596 |
|
|
2023
Q1 | $643K | Hold |
920,517
| – | – | ﹤0.01% | 4042 |
|
|
2022
Q4 | $828K | Buy |
920,517
+11,127
| +1% | +$32.2K | ﹤0.01% | 3971 |
|
|
2022
Q3 | $5.46M | Buy |
909,390
+269,026
| +42% | +$1.53M | ﹤0.01% | 3277 |
|
|
2022
Q2 | $2.65M | Sell |
640,364
-7,968
| -1% | -$28.1K | ﹤0.01% | 3683 |
|
|
2022
Q1 | $2.46M | Sell |
648,332
-6,514
| -1% | -$29.4K | ﹤0.01% | 3873 |
|
|
2021
Q4 | $2.95M | Buy |
654,846
+8,333
| +1% | +$42.3K | ﹤0.01% | 3877 |
|
|
2021
Q3 | $3.01M | Buy |
646,513
+2,212
| +0.3% | +$11.7K | ﹤0.01% | 3912 |
|
|
2021
Q2 | $4.54M | Buy |
644,301
+432,741
| +205% | +$2.33M | ﹤0.01% | 3655 |
|
|
2021
Q1 | $1.25M | Buy |
211,560
+22,752
| +12% | +$138K | ﹤0.01% | 3964 |
|
|
2020
Q4 | $870K | Sell |
188,808
-22,927
| -11% | -$98.8K | ﹤0.01% | 3858 |
|
|
2020
Q3 | $824K | Sell |
211,735
-176,965
| -46% | -$3.56M | ﹤0.01% | 3702 |
|
|
2020
Q2 | $11.2M | Buy |
388,700
+120,547
| +45% | +$2.79M | ﹤0.01% | 2719 |
|
|
2020
Q1 | $5.77M | Sell |
268,153
-34,640
| -11% | -$786K | ﹤0.01% | 2909 |
|
|
2019
Q4 | $5.96M | Buy |
302,793
+267,793
| +765% | +$3.81M | ﹤0.01% | 3107 |
|
|
2019
Q3 | $526K | Buy |
+35,000
| New | +$543K | ﹤0.01% | 3807 |
|
Vanguard Group's STSA Position: Q2 2023 in Review
Vanguard Group sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 920,517 shares — an estimated $643K sold.
Vanguard Group first reported a position in STSA in Q3 2019 and held it in 15 quarters. The position peaked at $11.2M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Vanguard Group reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 920,517 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $643K.
- Vanguard Group first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Vanguard Group's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $11.2M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.